Bionano Genomics Narrows Losses, Faces Going Concern Doubt

TL;DR

**BNGO is burning cash and needs to raise capital ASAP, or it's lights out despite narrowing losses.**

AI Summary

Bionano Genomics, Inc. reported a net loss of $8.5 million for the three months ended September 30, 2025, a significant improvement from the $44.2 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $18.5 million, substantially lower than the $91.9 million loss in the prior year. Total revenue increased to $7.4 million for the three months ended September 30, 2025, up from $6.1 million in 2024, driven by product revenue growth to $6.9 million from $6.0 million. However, total revenue for the nine months decreased to $20.6 million from $22.6 million. Operating expenses saw a drastic reduction, falling to $11.9 million for the three months ended September 30, 2025, from $35.5 million in 2024, primarily due to the absence of intangible asset impairment charges and lower restructuring costs. The company's cash and cash equivalents stood at $3.1 million as of September 30, 2025, down from $9.2 million at December 31, 2024, and it reported an accumulated deficit of $711.7 million. Management expressed substantial doubt about the company's ability to continue as a going concern within the next 12 months without additional funding.

Why It Matters

Bionano Genomics' ability to significantly reduce its net loss and operating expenses is a positive signal for investors, indicating improved cost management and a potential path towards profitability, especially with product revenue showing growth. However, the explicit 'going concern' warning and dwindling cash reserves ($3.1 million) present a critical challenge, raising questions about the company's long-term viability and its ability to fund ongoing research and development. This financial precariousness could impact employee morale and job security, while customers might face uncertainty regarding future product support and innovation. In the competitive genome analysis market, Bionano's need for immediate capital could hinder its ability to compete with larger, more financially stable players, potentially leading to market share erosion if new funding isn't secured promptly.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern within 12 months' due to recurring net losses and negative cash flows from operations. As of September 30, 2025, Bionano Genomics had only $3.1 million in cash and cash equivalents and an accumulated deficit of $711.7 million, having used $12.2 million in cash from operations during the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider this a high-risk speculative play. Monitor closely for news regarding successful capital raises or strategic partnerships; without new funding, the company's future is highly uncertain. Existing shareholders should evaluate their risk tolerance given the explicit going concern warning.

Financial Highlights

debt To Equity

0.59

revenue

$7,367,000

operating Margin

N/A

total Assets

$79,062,000

total Debt

$29,263,000

net Income

-$8,500,000

eps

N/A

gross Margin

45.74%

cash Position

$3,065,000

revenue Growth

+21.30%

Revenue Breakdown

Key Numbers

• $8.5M — Net Loss (Q3 2025) (Significantly reduced from $44.2M in Q3 2024)
• $18.5M — Net Loss (9M 2025) (Substantially lower than $91.9M in 9M 2024)
• $7.4M — Total Revenue (Q3 2025) (Increased from $6.1M in Q3 2024)
• $6.9M — Product Revenue (Q3 2025) (Increased from $6.0M in Q3 2024)
• $11.9M — Total Operating Expenses (Q3 2025) (Drastically reduced from $35.5M in Q3 2024)
• $3.1M — Cash and Cash Equivalents (As of September 30, 2025, down from $9.2M at Dec 31, 2024)
• $711.7M — Accumulated Deficit (As of September 30, 2025)
• $12.2M — Cash Used in Operations (9M 2025) (Indicates continued cash burn)
• 1-for-60 — Reverse Stock Split Ratio (Effected on January 24, 2025)
• 9,730,400 — Common Shares Outstanding (As of September 30, 2025, post-split)

Key Players & Entities

• Bionano Genomics, Inc. (company) — registrant
• Lineagen Inc. (company) — wholly-owned subsidiary
• SEC (regulator) — Securities and Exchange Commission
• $8.5 million (dollar_amount) — net loss for Q3 2025
• $44.2 million (dollar_amount) — net loss for Q3 2024
• $3.1 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $711.7 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $12.2 million (dollar_amount) — cash used in operations for the nine months ended September 30, 2025
• Nasdaq Capital Market (market) — exchange where common stock is registered

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: Management has expressed substantial doubt about the company's ability to continue as a going concern within the next 12 months without additional funding. The company's cash and cash equivalents were $3.1 million as of September 30, 2025, down from $9.2 million at December 31, 2024, indicating a significant cash burn.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $711.7 million as of September 30, 2025. This substantial deficit highlights a history of unprofitability and reliance on external financing.
• Revenue Decline (Nine Months) [medium — operational]: Total revenue for the nine months ended September 30, 2025, decreased to $20.6 million from $22.6 million in the prior year. This decline, particularly in service and other revenue, suggests potential challenges in market adoption or sales execution.
• Decreasing Cash Position [high — financial]: Cash and cash equivalents decreased from $9.2 million at December 31, 2024, to $3.1 million at September 30, 2025. This sharp reduction in liquidity exacerbates the going concern risk.
• High Cost of Revenue (Q3 2025) [medium — operational]: Despite increased product revenue in Q3 2025, the cost of product revenue was $3.8 million compared to $14.3 million in Q3 2024. While this is a significant reduction, it's important to monitor if margins are sustainable.
• Stock Dilution Risk [medium — financial]: The company effected a 1-for-60 reverse stock split on January 24, 2025. While this increases the share price, it can also signal underlying financial distress and may lead to further dilution if additional capital is raised through equity offerings.

Industry Context

Bionano Genomics operates in the rapidly evolving field of genomic analysis, focusing on long-read sequencing technology. The industry is characterized by intense competition from established players and emerging technologies. Key trends include the increasing demand for advanced genomic solutions in research, diagnostics, and personalized medicine, as well as the ongoing development of more efficient and cost-effective sequencing platforms.

Regulatory Implications

As a company in the life sciences and diagnostics sector, Bionano Genomics is subject to various regulatory requirements, including those related to product development, manufacturing, and marketing. Compliance with regulations from bodies like the FDA (if applicable to their products) and international equivalents is crucial. Changes in healthcare policy or reimbursement landscapes could also impact market access and adoption of their technologies.

What Investors Should Do

1. Monitor cash burn and funding runway closely.
2. Evaluate the sustainability of revenue growth and cost reductions.
3. Assess the impact of the reverse stock split.
4. Analyze the competitive landscape and technological differentiation.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $8.5 million and total revenue of $7.4 million, showing improved quarterly performance but continued cash burn.
• 2025-01-24: Reverse Stock Split — A 1-for-60 reverse stock split was effected, impacting the number of outstanding shares and potentially the stock price perception.
• 2025-09-30: Cash and Cash Equivalents — Stood at $3.1 million, a significant decrease from $9.2 million at the end of 2024, raising going concern issues.
• 2025-09-30: Accumulated Deficit — Reached $711.7 million, underscoring the company's long-term unprofitability.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $44.2 million and total revenue of $6.1 million, providing a baseline for year-over-year comparison.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents were $9.2 million, serving as the starting point for the current year's cash position.

Glossary

Accumulated Deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates the company's historical unprofitability and its cumulative losses, standing at $711.7 million as of September 30, 2025.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (Management's doubt about Bionano Genomics' ability to continue as a going concern highlights significant financial risks and the need for immediate funding.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of a company, typically to increase the share price. (Bionano Genomics executed a 1-for-60 reverse stock split on January 24, 2025, affecting its share count and potentially its market perception.)

Cost of Revenue

The direct costs attributable to the production or delivery of goods or services sold by a company. (A significant reduction in cost of product revenue for Q3 2025 ($3.8M vs $14.3M in Q3 2024) contributed to improved net loss, but needs monitoring for sustainability.)

Operating Expenses

Expenses a business incurs in its normal course of operations, excluding cost of goods sold. (Drastic reduction in operating expenses to $11.9 million in Q3 2025 from $35.5 million in Q3 2024, primarily due to absence of impairment charges and lower restructuring costs, significantly improved net loss.)

Convertible Debentures Payable

Debt instruments that can be converted into a predetermined amount of the issuer's equity. (The balance decreased from $20.4 million at December 31, 2024, to $9.8 million at September 30, 2025, indicating repayment or conversion.)

Year-Over-Year Comparison

Compared to the prior year, Bionano Genomics has demonstrated a significant improvement in its net loss for the third quarter of 2025, reducing it from $44.2 million to $8.5 million. This was largely driven by a drastic reduction in operating expenses, which fell from $35.5 million to $11.9 million, primarily due to lower restructuring costs and the absence of impairment charges. However, total revenue for the nine-month period declined to $20.6 million from $22.6 million, indicating a mixed performance. The company's cash position has also deteriorated, falling from $9.2 million at the end of 2024 to $3.1 million, intensifying concerns about its ability to continue as a going concern.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Cap

Filing Documents

• bngo-20250930.htm (10-Q) — 2002KB
• bngo-20250930xexx311.htm (EX-31.1) — 10KB
• bngo-20250930xexx321.htm (EX-32.1) — 8KB
• 0001411690-25-000093.txt ( ) — 9835KB
• bngo-20250930.xsd (EX-101.SCH) — 56KB
• bngo-20250930_cal.xml (EX-101.CAL) — 102KB
• bngo-20250930_def.xml (EX-101.DEF) — 333KB
• bngo-20250930_lab.xml (EX-101.LAB) — 819KB
• bngo-20250930_pre.xml (EX-101.PRE) — 586KB
• bngo-20250930_htm.xml (XML) — 1444KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 3 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 6 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited) 8 Notes to Condensed Consolidated Financial Statements (Unaudited) 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 32

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 47

Controls and Procedures

Item 4. Controls and Procedures 47

OTHER INFORMATION

PART II. OTHER INFORMATION 48

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 48

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 96

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 96

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 96

Other Information

Item 5. Other Information 96

Exhibits

Item 6. Exhibits 97

SIGNATURES

SIGNATURES 99 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS BIONANO GENOMICS, INC. Condensed Consolidated Balance Sheets (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 3,065,000 $ 9,173,000 Investments 18,516,000 302,000 Accounts receivable, net 4,526,000 4,752,000 Inventory 7,049,000 11,121,000 Prepaid expenses and other current assets 5,378,000 3,141,000 Restricted investments 10,266,000 11,000,000 Total current assets 48,800,000 39,489,000 Restricted cash — 400,000 Property and equipment, net 16,172,000 19,219,000 Operating lease right-of-use assets 3,497,000 1,804,000 Finance lease right-of-use assets 3,146,000 3,299,000 Intangible assets, net 5,685,000 9,705,000 Other long-term assets 1,762,000 2,754,000 Total assets $ 79,062,000 $ 76,670,000 Liabilities and stockholders' equity Current liabilities: Accounts payable 5,990,000 6,962,000 Accrued expenses 4,706,000 5,641,000 Contract liabilities 1,180,000 1,128,000 Operating lease liability 1,025,000 2,991,000 Finance lease liability 251,000 260,000 Convertible debentures payable (at fair value) 9,825,000 20,362,000 Total current liabilities 22,977,000 37,344,000 Operating lease liability, net of current portion 2,599,000 145,000 Finance lease liability, net of current portion 3,495,000 3,539,000 Long-term contract liabilities 192,000 267,000 Total liabilities $ 29,263,000 $ 41,295,000 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value, 400,000,000 shares authorized at September 30, 2025 and December 31, 2024; 9,730,400 and 1,865,400 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,000 — Additional paid-in capital 761,479,000 728,573,000 Accumulated deficit ( 711,687,000

View Full Filing

View this 10-Q filing on SEC EDGAR